Subject: Prostate Px, Post-Op Px

Effective Date: October 25, 2011

Department(s): Utilization Management

Policy: Prostate Px and Post-Op Px, proprietary systems pathology models for predicting prostate cancer disease severity and recurrence risk using a combination of clinical characteristics, pathology and molecular markers, including androgen receptors are not reimbursable under Plans administered by QualCare, Inc.

Objective: To assure proper and consistent reimbursement and to limit reimbursement to interventions of proven efficacy.

Procedure: Requests for reimbursement for the Prostate Px and Post-OP Px will be denied. There is insufficient documentation in the peer-reviewed medical literature that the models can alter clinical management decisions resulting in improved health outcomes. They are, therefore, deemed experimental, investigational, or unproven.
References


Drafted By/On: M McNeil, MD 10/03/11
Approved By/On: 10/25/2011
Reviewed w/o revision By/Date: MMcNeil, MD 07/14/15
Approved for retirement By: QM Committee 7/28/15

Services addressed in this policy are removed from the market.

*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.